After two years of the covid-19 pandemic period, the conference gave us the opportunity to network in-person with health economics and outcomes research (HEOR) experts and thought leaders, and to discuss with a global audience on how we will establish a more efficient and sustainable health system, sharing value for patients and technology developers.

The Econcare team attended this year's conference and presented interesting findings in five posters that you can find below: 

Cost-Effectiveness Analysis of Bimekizumab in Patients With Moderate-to-Severe Plaque Psoriasis in Greece

Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece

Cost-Effectiveness of Brexucabtagene Autoleucel (Brexu-cel, CAR-T) for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma in Greece (Top 5% Finalist for the ISPOR Europe 2022 Research Presentation Awards 🥇) 

A Budget Impact Analysis of Introducing a New Combination of Atorvastatin and Ezetimibe in Greece

Budget Impact Analysis of Bimekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Greece